MedTrace Logo

Biomarkers For Immune Checkpoint Inhibitors

NCT04204434 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 119

Last updated 2024-08-13

No results posted yet for this study

Summary

This is a laboratory, non-treatment study. Immune checkpoint inhibitors are a type of immunotherapy that stimulates a patients immune system to fight their cancer. Immune checkpoint inhibitors are standard, FDA approved treatment for certain types of cancers such as melanoma, lung cancer, kidney cancer and bladder cancer. The laboratories of Dr. Jack Elias and Dr. Chun Geun Lee at Brown University are studying how immune checkpoint inhibitors work.Kintai Therapeutics is a biotech company in Cambridge Massachusetts that will focus on the molecules present in the GI tract, including the stomach, small intestine and colon.

Conditions

Sponsors & Collaborators

  • Brown University

    collaborator OTHER

  • Rhode Island Hospital

    lead OTHER

Principal Investigators

  • Howard Safran, MD · Rhode Island Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-29
Primary Completion
2021-12-31
Completion
2024-04-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04204434 on ClinicalTrials.gov